The abstract is read at the publisher; the summary is JClub's.
TROP2 normalized membrane ratio (NMR) predicts longer progression-free survival with datopotamab deruxtecan in advanced nonsquamous NSCLC, with median 7.2 vs 4.0 months.
- Why it matters: Conventional pathologist immunohistochemistry scoring for TROP2 does not predict response to TROP2-directed antibody-drug conjugates in NSCLC, leaving a biomarker gap.
- What they did: A supervised computational pathology method (TROP2 QCS) quantified membrane and cytoplasmic TROP2 on immunohistochemistry slides, defining NMR in TROPION-PanTumor01 (n=115) and optimizing/validating cut-points in TROPION-Lung01 (n=221; biomarker-evaluable n=352).
- The result: In TROPION-Lung01, PFS was longer for TROP2 NMR-positive vs -negative patients on Dato-DXd (HR 0.40, 95% CI 0.25–0.64), but not on docetaxel (HR 0.94, 95% CI 0.59–1.49), with interaction P=0.0098.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.